Agios Pharmaceuticals, Inc. (AGIO) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	98.3M	54.0M	36.5M	26.8M	14.2M
Cost of Revenue	11.9M	11.5M	4.2M	9.5M	1.7M
Gross Profit	86.5M	42.5M	32.3M	17.3M	12.5M
Operating Expenses
R&D Expense	352.8M	334.4M	301.3M	288.9M	279.9M
SG&A Expense	192.7M	180.3M	156.8M	119.9M	121.7M
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	545.5M	514.6M	458.1M	408.8M	401.6M
Cost and Expenses	557.4M	526.2M	462.2M	418.3M	403.3M
Operating Income (EBIT)	(459.0M)	(472.1M)	(425.7M)	(391.5M)	(389.0M)
Non-Operating
Interest Income	46.3M	56.4M	48.1M	33.3M	12.8M
Interest Expense	—	—	—	—	—
Net Interest Income	46.3M	56.4M	48.1M	33.3M	12.8M
Other Non-Op Income/Expense	46.7M	58.3M	1.1B	39.4M	157.2M
Non-Operating Income (excl Interest)	(36.9M)	(58.3M)	(1.1B)	(39.4M)	(157.2M)
EBT (Pre-Tax Income)	(412.3M)	(413.8M)	718.0M	(352.1M)	(231.8M)
Income Tax Expense	(1.0M)	(1.0M)	44.2M	—	—
Bottom Line
Net Income	(411.3M)	(412.8M)	673.7M	(352.1M)	(231.8M)
Earnings from Cont. Ops	(411.3M)	(412.8M)	673.7M	(352.1M)	(231.8M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(411.3M)	(412.8M)	673.7M	(352.1M)	(231.8M)
Per Share
Basic EPS	($7.01)	($7.12)	$11.86	($6.33)	($4.23)
Diluted EPS	($7.01)	($7.12)	$11.64	($6.33)	($4.23)
Revenue Per Share	$1.65	$0.93	$0.64	$0.48	$0.26
Shares
Basic Shares Outstanding	59.5M	58.0M	56.8M	55.7M	54.8M
Diluted Shares Outstanding	59.5M	58.0M	57.9M	55.7M	54.8M
Profitability Metrics
EBITDA	(416.8M)	(408.6M)	723.6M	(345.5M)	(223.2M)
D&A	5.4M	5.2M	5.7M	6.6M	8.6M
EBIT	(422.2M)	(413.8M)	718.0M	(352.1M)	(231.8M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026